From new vaccines to the advent of new neurotoxinsPhysicians weigh in expectations for new developments within all facets of dermatology from pediatric dermatology to dermatopathology.
Managing hedgehog therapies for basal cell carcinomaWhile the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Multidisciplinary care improves patient outcomesMultidisciplinary skin cancer care is an approach that might not only improve patient outcomes, but also professional satisfaction, researchers reported at AAD 2018 this week in San Diego.
Revised tumor classification for head and neck CSCCAJCC updates classifications for head and neck cutaneous squamous cell carcinoma. AJCC 8 expands criteria for cases that now qualify to be T3. Now, T3 and T4 capture more poor outcomes.
Ruler is better than eye for pigment measurePhysicians should measure pigmented lesion diameter with a ruler rather than estimating via landmarks or the naked eye, a study shows.
Guide to ID at-risk patientsA recent study explored varying statistical approaches to a metastatic risk model for identifying SCC tumors at high risk of metastasis. Researchers identified six risk factors.
Revised melanoma staging criteriaStaging system is derived from a new dataset of patients from 10 cancer centers around the world. Dermatologists should consider AJCC tumor characteristics as well as other factors in risk assessment, counseling, and follow-up plans for patients. Update takes effect in January 2018.
Repurposed antifungal exhibits promising results
Repurposed antifungal exhibits promising resultsA novel oral formulation of itraconazole designed to improve bioavailability is leveraging its activity as a Hedgehog pathway inhibitor to provide a low toxicity, effective treatment for patients with BCC Nevus Syndrome. Data show potential for rapid therapeutic benefit.
SLNB for melanomaBiopsy can differentiate risk level for patients, but selectively indicated
Melanoma tumor suppressorA known oncogene previously associated with carcinomas of the breast, liver, ovaries, and colon appears to suppress the growth of melanoma cells, a team of researchers reported recently in Cell Reports.


View Results